Pilot study of Bortezomib for Patients with Imatinib-Refractory Chronic Myeloid Leukemia in Chronic or Accelerated Phase

BACKGROUND: Proteasome inhibitors are anticancer compounds that disrupt the proteolytic activity of the proteasome and lead to tumor cell growth arrest and apoptosis. Bortezomib is a proteasome inhibitor that is currently approved for use in multiple myeloma and mantle cell lymphoma. It induces apop...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Lymphoma Myeloma Leuk
Main Authors: Santos, Fabio P S, Kantarjian, Hagop, McConkey, David, O'Brien, Susan, Faderl, Stefan, Borthakur, Gautam, Ferrajoli, Alessandra, Wright, John, Cortes, Jorge
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4405186/
https://ncbi.nlm.nih.gov/pubmed/21816374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2011.06.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados